GTCR acquires Zentiva

GTCR has finalized its acquisition of Zentiva from Advent International, significantly broadening its presence in the European generics pharmaceutical market. The transaction emphasizes GTCR’s strategy of enhancing its healthcare investment portfolio, although financial terms were not disclosed.

Zentiva operates as a major producer and supplier of generic, branded, and over-the-counter pharmaceuticals, with a reach extending to over 100 million people across more than 40 countries. The company is recognized for its robust research and development capacity, along with a strong track record in clinical quality and product reliability. GTCR plans to collaborate with Zentiva's leadership, including CEO Steffen Saltofte and Executive Chairperson Kieran Murphy, to propel Zentiva’s growth, invest in product development, and expand its portfolio, aiming to improve access to affordable medicines throughout Europe.

This acquisition is in line with GTCR's ongoing focus on investments in the healthcare sector, driven by the mounting need for cost-effective pharmaceutical solutions amid global healthcare system pressures. Zentiva's scale, manufacturing capabilities, and expansive regional presence are expected to facilitate crucial access to essential medicines, promoting sustainable healthcare delivery. Advisors on the deal included, on GTCR's side, Barclays, BNP Paribas, Morgan Stanley, and Kirkland & Ellis, while Advent International was advised by Goldman Sachs, PJT Partners, and Freshfields.

For GTCR, partnering with Zentiva aligns with broader efforts by policymakers to enhance access to essential medications, as noted by Sean Cunningham, Managing Director and Head of Healthcare at GTCR. Zentiva’s competitive edge in low-cost manufacturing and its geographic reach are anticipated to position it to enhance its market position and deliver sustained growth.

Looking forward, Zentiva’s management anticipates leveraging GTCR’s industry expertise to accelerate growth. As the deal marks a pivotal point in Zentiva’s trajectory post its transformation under Advent International, GTCR's involvement is expected to further fortify Zentiva’s market standing. The focus will remain on broadening the availability of cost-effective, high-quality medical treatments across Europe.